department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

TALPHERA, INC. ($TLPH) · pharmadog

PUBLIC COMPANY

$TLPHTALPHERA, INC.

San Mateo, CA, USupdated 8h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

1

phase 3

0

catalysts ytd

2

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Marketed

sufentanil citrate

Post-Operative Pain

Mu-type opioid receptor

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1) · drug shortage (1)

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view TALPHERA, INC. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$TLPH

SEC CIK

0001427925

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

TALPHERA, INC. earnings

Sufentanil Citrate Injection shortage — Hospira, Inc., a Pfizer Company

$TLPH1.1600+8.41%

Data sources

SEC EDGAR · openFDA

last refreshed 47m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

N/ANafamostat Efficacy in Phase 3 Registrational CRRT Studyrecruitingn=70

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 13, 26BUYAngotti Vincent J.· CHIEF EXECUTIVE OFFICER213,310 sh @ $0.59$125K↗
Feb 12, 26BUYAngotti Vincent J.· CHIEF EXECUTIVE OFFICER105,364 sh @ $0.81$86K↗
Feb 12, 26BUYASADORIAN RAFFI· Chief Financial Officer45,000 sh @ $0.81$37K↗
Feb 12, 26BUYDasu Badri N· Chief Engineering Officer35,000 sh @ $0.81$28K↗
Feb 12, 26BUYAslam Shakil· Chief Medical Officer35,000 sh @ $0.81$28K↗

routine RSU / option mechanics (6)

Apr 2, 26tax coverAngotti Vincent J. · CHIEF EXECUTIVE OFFICER9,938 sh
Apr 2, 26tax coverASADORIAN RAFFI · Chief Financial Officer2,444 sh
Apr 2, 26tax coverDasu Badri N · Chief Engineering Officer2,444 sh
Apr 2, 26tax coverAslam Shakil · Chief Medical Officer2,118 sh
Mar 13, 26grantNantahala Capital Management, LLC · 4,266,211 sh

Feb 14, 26

tax cover

Angotti Vincent J. · CHIEF EXECUTIVE OFFICER

9,559 sh

$TLPH1.1600+8.41%

$TLPH1.1600+8.41%